Literature DB >> 23286209

Non-alcoholic fatty liver disease as an independent manifestation of the metabolic syndrome: results of a US national survey in three ethnic groups.

Mark M Smits1, George N Ioannou, Edward J Boyko, Kristina M Utzschneider.   

Abstract

BACKGROUND AND AIM: The metabolic syndrome (MetS) and each of its components are strongly associated with non-alcoholic fatty liver disease (NAFLD). This has led many investigators to suggest that NAFLD is an independent component of the MetS. We formally tested this hypothesis using confirmatory factor analysis, which allows comparison of different models, with or without including NAFLD as a component of the MetS.
METHODS: We analyzed data from 3846 subjects of the Third National Health and Nutrition Examination Survey (1988-1994). NAFLD was defined by increased liver fat measured by ultrasonography.
RESULTS: MetS by Adult Treatment Panel III criteria was present in 20.5%, and 30.2% had NAFLD, defined as mild, moderate, or severe ultrasonographic steatosis. Using confirmatory factor analysis, a basic model representing the MetS using its currently accepted components (glucose, waist, triglyceride/high-density lipoprotein ratio, and mean arterial pressure) showed excellent goodness-of-fit statistics. Addition of NAFLD to the model as a fifth independent variable decreased model fit, suggesting that NAFLD is not an additional independent component of the MetS. Analysis by ethnicity showed that addition of NAFLD decreased model fit in Whites but resulted in minor improvements in non-Hispanic Blacks and Mexican Americans.
CONCLUSIONS: The MetS is strongly associated with NAFLD. However, we found no evidence that NAFLD is an independent component or manifestation of the MetS. Interestingly, ethnic differences might be important in this relationship and require further study. Published 2013. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Mesh:

Year:  2013        PMID: 23286209     DOI: 10.1111/jgh.12106

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  52 in total

1.  Nutritional and metabolic regulation of the metabolite dimethylguanidino valeric acid: an early marker of cardiometabolic disease.

Authors:  Jibran A Wali; Yen Chin Koay; Jason Chami; Courtney Wood; Leo Corcilius; Richard J Payne; Roman N Rodionov; Andreas L Birkenfeld; Dorit Samocha-Bonet; Stephen J Simpson; John F O'Sullivan
Journal:  Am J Physiol Endocrinol Metab       Date:  2020-07-14       Impact factor: 4.310

Review 2.  Epidemiology of fatty liver: an update.

Authors:  Giorgio Bedogni; Valerio Nobili; Claudio Tiribelli
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

3.  XBP1s Is an Anti-lipogenic Protein.

Authors:  Hilde Herrema; Yingjiang Zhou; Dongyan Zhang; Justin Lee; Mario Andres Salazar Hernandez; Gerald I Shulman; Umut Ozcan
Journal:  J Biol Chem       Date:  2016-06-20       Impact factor: 5.157

Review 4.  Gender and racial differences in nonalcoholic fatty liver disease.

Authors:  Jen-Jung Pan; Michael B Fallon
Journal:  World J Hepatol       Date:  2014-05-27

5.  Mitigating the scourge of non-alcoholic fatty liver disease in Ghana.

Authors:  Adwoa Agyei-Nkansah
Journal:  Ghana Med J       Date:  2017-09

Review 6.  Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.

Authors:  Letiția Adela Maria Streba; Cristin Constantin Vere; Ion Rogoveanu; Costin Teodor Streba
Journal:  World J Gastroenterol       Date:  2015-04-14       Impact factor: 5.742

7.  Relationship between non-alcoholic fatty liver disease and benign prostatic hyperplasia/lower urinary tract symptoms: new insights from an Italian cross-sectional study.

Authors:  Giorgio Ivan Russo; Sebastiano Cimino; Eugenia Fragalà; Salvatore Privitera; Sandro La Vignera; Rosita Condorelli; Aldo E Calogero; Mario Chisari; Tommaso Castelli; Vincenzo Favilla; Giuseppe Morgia
Journal:  World J Urol       Date:  2014-09-05       Impact factor: 4.226

8.  Association between PNPLA3 (rs738409), LYPLAL1 (rs12137855), PPP1R3B (rs4240624), GCKR (rs780094), and elevated transaminase levels in overweight/obese Mexican adults.

Authors:  Yvonne N Flores; Rafael Velázquez-Cruz; Paula Ramírez; Manuel Bañuelos; Zuo-Feng Zhang; Hal F Yee; Shen-Chih Chang; Samuel Canizales-Quinteros; Manuel Quiterio; Guillermo Cabrera-Alvarez; Nelly Patiño; Jorge Salmerón
Journal:  Mol Biol Rep       Date:  2016-10-17       Impact factor: 2.316

Review 9.  Transient elastography (FibroScan(®)) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?

Authors:  Ivana Mikolasevic; Lidija Orlic; Neven Franjic; Goran Hauser; Davor Stimac; Sandra Milic
Journal:  World J Gastroenterol       Date:  2016-08-28       Impact factor: 5.742

10.  Longitudinal association of obesity, metabolic syndrome and diabetes with risk of elevated aminotransferase levels in a cohort of Mexican health workers.

Authors:  Yvonne N Flores; Allyn Auslander; Catherine M Crespi; Michael Rodriguez; Zuo-Feng Zhang; Francisco Durazo; Jorge Salmerón
Journal:  J Dig Dis       Date:  2016-05       Impact factor: 2.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.